Medicare to Cover Lung Cancer Screening

Article

With the agency's proposal to cover lung cancer screening, focus turns to implementation and increasing cures.

The Centers for Medicare & Medicaid Services (CMS) announced that the agency plans to cover lung cancer screening for certain former and current smokers, a decision that could affect an estimated 4 million people.

The federal agency issued a draft guidance on Nov. 10 that outlined annual lung cancer screenings with low-dose computed tomography (LDCT), as well as counseling about the process, as a preventive service for individuals aged 55 to 74 years old with no signs of lung disease. Individuals must have a history of smoking at least 30-pack years (eg. one pack per day for 30 years) and be current or former smokers who have quit within the past 15 years.

“Tens of thousands of lives will be saved by providing America’s seniors with fair and equitable access to the same lifesaving lung cancer screening that is now being offered to those with private insurance,” said Fenton Ambrose, president and CEO of the Lung Cancer Alliance, in a statement issued by the organization. "Now, we will focus our attention on making sure those who would benefit most from this screening actually get screened.”

[“The Time Has Come For Lung Cancer Screening” by Laurie Fenton, CURE 2012]

The decision follows the recommendation by the U.S. Preventive Services Task Force this past December for high-risk individuals to receive lung cancer screening, which ultimately made it a requirement for private insurers to cover the service in 2015. In April, a Medicare advisory committee voted against recommending lung cancer screening with LDCT out of concern that risks, such as false positives, unnecessary needle biopsies and risky surgery, would outweigh potential benefits. In response, more than 175 members of Congress signed letters this past September urging CMS to cover LDCT.

Richard Wender, chief cancer control officer with the American Cancer Society, said the society, along with many other organization, has been working with Medicare on a plan to cover the practice.

“We had the very interesting possibility that if Medicare did not provide coverage, you’d be covered (under private insurance) until you hit Medicare—and as your risk gets higher as you get older, you’d no longer be covered,” he said. “We like the way it turned out.”

While Medicare plans to cover screening for high-risk individuals, it will only occur at accredited facilities. In addition, data from each lung cancer screening performed under Medicare will be collected for a national registry to produce additional research regarding the preventive practice.

“We’ve learned a lot since when mammography was first recommended,” Wender says. “This really reflects a modern-day screening decision that recognizes from the outset how important it is to do it right.”

In addition to the evidence gathered from multiple lung cancer screening studies, guidelines also have narrowed in on a high-risk group and highlighted the importance of screening at accredited facilities. Because the number of these facilities may be limited, one goal is to broaden accessibility, says Wender.

“First priority is to build capacity to make sure the centers can meet specific quality program requirements,” he says. “Right along the same time will be some broad public education about who should consider screening, which (may involve) a large learning curve…that this is really only for people who have a very high risk of lung cancer.”

James L. Mulshine, vice president and associate provost for research at Rush University Medical Center in Chicago, is on the board of the International-Early Lung Cancer Action Project, one of the lung cancer screening trials that provided evidence of benefit. The CMS ruling presents an opportunity to not only cure lung cancer in high-risk individuals, he says, but also motivate current smokers to quit.

“We now have to work to make sure that broad access to high-quality screening service with informed decision making and access to smoking cessation occurs for those at highest risk for this cancer,” Mulshine says.

Providing coverage for screening, as well as the discussion around it and smoking cessation, will be key for patients, but also for primary-care physicians and internists, who will be recommending the screening for their patients.

“This was a critical step. We can’t do anything without coverage, but in some respects, we recognize that the hard work is just starting—to create national capacity to reach as many people as possible with high-quality screening,” Wender says.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL